Trials / Unknown
UnknownNCT03225963
Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 60 (estimated)
- Sponsor
- Taichung Veterans General Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Bevacizumab has become the standard of care of recurrent glioblastoma based on promising clinical trial results with with response rates up to 50% and progression-free survival up to 9 months. In our study, we set to find the serum angiogenesis biomarkers of bevacizumab response.
Detailed description
Pre-chemoradiation and post-chemoradiation peripheral blood will be obtained to see if there are some angiogenesis biomarker available for prediction of bevacizumab response later.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Chemoradiation with temozolomide |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2018-07-31
- Completion
- 2018-07-31
- First posted
- 2017-07-21
- Last updated
- 2017-07-24
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT03225963. Inclusion in this directory is not an endorsement.